Drug Trial Radar · NCT07354477
Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation
Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Feb 20, 2026
Primary completion
Oct 1, 2026
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- Qlaris Bio, Inc.Industry
- Sponsor type
- Industry
- First posted
- Jan 21, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG
Conditions
- Non-proliferative Diabetic Retinopathy (NPDR)
- Open-angle Glaucoma (OAG)
- Normal Tension Glaucoma (NTG)
Interventions
QLS-111 Ophthalmic Solution (0.015%)Drug
QLS-111 (0.015%) administered BID for 7 days OU.
QLS-111 Ophthalmic Solution (0.075%)Drug
QLS-111 (0.075%) administered BID for 7 days OU. Follows the 7 days where QLS-111 (0.015%) is administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in blood flow to the posterior segment of the eye.Time frame: Days 1 through 22
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Stanford University, Dept. of Ophthalmology
Palo Alto, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.